On 8 August 2018, in an unprecedented regulatory action, the China National Drug Administration (CNDA) called on international pharmaceutical companies to bring 48 new drugs to China. These new drugs are viewed to be urgently needed in China and have already been approved and marketed in the U.S., EU, and Japan for rare diseases or other life-threatening diseases and conditions.
Please see full publication below for more information.
